Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian; ENESTnd Investigators; Ole Weis Bjerrum

doi:10.1056/NEJMoa0912614

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

Giuseppe Saglio, Dong-Wook Kim, Surapol Issaragrisil, Philipp le Coutre, Gabriel Etienne, Clarisse Lobo, Ricardo Pasquini, Richard E Clark, Andreas Hochhaus, Timothy P Hughes, Neil Gallagher, Albert Hoenekopp, Mei Dong, Ariful Haque, Richard A Larson, Hagop M Kantarjian, ENESTnd Investigators, Ole Weis Bjerrum

1441 Citationer (Scopus)

Abstract

Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase.

Originalsprog	Engelsk
Tidsskrift	New England Journal of Medicine
Vol/bind	362
Udgave nummer	24
Sider (fra-til)	2251-9
Antal sider	9
ISSN	0028-4793
DOI	https://doi.org/10.1056/NEJMoa0912614
Status	Udgivet - 17 jun. 2010

Adgang til dokumentet

10.1056/NEJMoa0912614

Citationsformater

Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., Gallagher, N., Hoenekopp, A., Dong, M., Haque, A., Larson, R. A., Kantarjian, H. M., ENESTnd Investigators, & Bjerrum, O. W. (2010). Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 362(24), 2251-9. https://doi.org/10.1056/NEJMoa0912614

Saglio, G, Kim, D-W, Issaragrisil, S, le Coutre, P, Etienne, G, Lobo, C, Pasquini, R, Clark, RE, Hochhaus, A, Hughes, TP, Gallagher, N, Hoenekopp, A, Dong, M, Haque, A, Larson, RA, Kantarjian, HM, ENESTnd Investigators & Bjerrum, OW 2010, 'Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia', New England Journal of Medicine, bind 362, nr. 24, s. 2251-9. https://doi.org/10.1056/NEJMoa0912614

@article{d4c62eae156c4c198ddbfbf355d3618c,

title = "Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia",

abstract = "Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase.",

author = "Giuseppe Saglio and Dong-Wook Kim and Surapol Issaragrisil and {le Coutre}, Philipp and Gabriel Etienne and Clarisse Lobo and Ricardo Pasquini and Clark, {Richard E} and Andreas Hochhaus and Hughes, {Timothy P} and Neil Gallagher and Albert Hoenekopp and Mei Dong and Ariful Haque and Larson, {Richard A} and Kantarjian, {Hagop M} and {ENESTnd Investigators} and Bjerrum, {Ole Weis}",

note = "2010 Massachusetts Medical Society",

year = "2010",

month = jun,

day = "17",

doi = "10.1056/NEJMoa0912614",

language = "English",

volume = "362",

pages = "2251--9",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachusetts Medical Society",

number = "24",

}

TY - JOUR

T1 - Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

AU - Saglio, Giuseppe

AU - Kim, Dong-Wook

AU - Issaragrisil, Surapol

AU - le Coutre, Philipp

AU - Etienne, Gabriel

AU - Lobo, Clarisse

AU - Pasquini, Ricardo

AU - Clark, Richard E

AU - Hochhaus, Andreas

AU - Hughes, Timothy P

AU - Gallagher, Neil

AU - Hoenekopp, Albert

AU - Dong, Mei

AU - Haque, Ariful

AU - Larson, Richard A

AU - Kantarjian, Hagop M

AU - ENESTnd Investigators

AU - Bjerrum, Ole Weis

N1 - 2010 Massachusetts Medical Society

PY - 2010/6/17

Y1 - 2010/6/17

N2 - Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase.

AB - Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase.

U2 - 10.1056/NEJMoa0912614

DO - 10.1056/NEJMoa0912614

M3 - Journal article

C2 - 20525993

SN - 0028-4793

VL - 362

SP - 2251

EP - 2259

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 24

ER -

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater